Stifel raises Tandem Diabetes stock price target after revenue beat
ArchivedSingle Source|2 articles|1 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Stifel raised the stock price target for Tandem Diabetes after a revenue beat.
- •Tandem Diabetes reported revenue figures above analyst expectations.
- •Stifel also raised the stock price target for Guardant Health based on guidance.
- •The updates were reported on February 20, 2026.
What Could Happen If...
- ▸If Tandem Diabetes continues to report revenue beats in upcoming quarters Stifel and other analysts may further raise price targets, potentially increasing investor interest.
Market Exposure
StocksTandem Diabetes stockUpward Pressure
The revenue beat and raised price target by Stifel may increase demand for the stock.
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Instruments
Organizations
Source Coverage
FINANCE
2 articles
More coverage on this story
- More on Guardant Health stock
- More on Tandem Diabetes stock
- More on Guardant Health
- More on Stifel
Signals
Single-block coverage
Related Events
▸Lattice Semiconductor stock price target raised to $110 from $80 at StifelArchived▸Piper Sandler upgrades Tandem Diabetes stock on pricing benefitsArchived▸Beta Technologies upgraded at Jefferies on near-term growth catalystsArchived▸Stifel Maintains Manhattan Associates Stock Rating After ConferenceArchived▸Citizens lowers Mirum Pharmaceuticals price target on valuation